Merck & Co. reported a 5% revenue increase to $16.6 billion in Q2 2026, driven by strong sales of its cancer drug KEYTRUDA at $8.4 billion and significant growth in pipeline products WELIREG and WINREVAIR. Analysts, including Daiwa, upgraded Merck to "Outperform" with a price target of $143, indicating nearly 10% upside potential. The company's robust drug development and expanding international sales support a positive outlook, making it a strong player in the pharmaceutical industry.
President Trump's executive order to separate the combined MMR vaccine into individual shots faces significant regulatory and manufacturing challenges, with FDA approval potentially taking up to 10 years. Merck and GSK, the only licensed producers of...
Merck & Co. saw a significant stock sale by its Animal Health President, Richard R. DeLuca, who sold 11,099 shares worth about $1.46 million. The company reported strong Q2 results with revenues up 5% to $16.61 billion, driven by its cancer drug Keyt...
Revolution Medicines closed at $205.55 on August 11, 2026, reaching a $44.1 billion market cap driven by its promising RAS-targeting oncology pipeline. The company has no current product revenue but shows strong clinical results, especially with dara...
Bio-Techne Corporation reported flat revenue of $1.2 billion for fiscal year 2026, with a 3% organic revenue increase in Q4. GAAP EPS rose to $1.16 for the full year from $0.46 last year, while adjusted EPS slightly increased to $1.93. The company hi...
President Donald Trump signed an executive order to separate the combined MMR vaccine into three individual shots, citing unproven claims linking the combined vaccine to autism. Medical experts strongly reject this, emphasizing the vaccine's safety a...
